F
ArriVent BioPharma, Inc. — Earnings Quality Grade F
AVBP · Healthcare
Major red flags
Revenue
$0M
2025
Net Income
-$166M
2025
Gross Margin
—
Free Cash Flow
-$161M
01
Screening Summary
7
Passed
1
Watch
1
Failed
—
M-Score
管理层信号
最近 SEC 8-K 文件中未发现 CEO、CFO、董事会或审计负责人变动信号。
02
Financial Trends
Revenue & Net Income ($B)
Margins (%)
03
18-Point Screening
01
Revenue Quality
—
A1DSO Change
Insufficient data
—
A2AR vs Revenue Growth
Insufficient data
—
A3Revenue vs CFFO
Insufficient data
02
Expense Quality
✓
B1Inventory vs COGS
No material inventory
—
B2CapEx vs Revenue
Insufficient data
—
B3SG&A Ratio
Insufficient data
—
B4Gross Margin
Insufficient data
03
Cash Flow Quality
✗
C1CFFO vs Net Income
CFFO < Net Income for 3 consecutive years
Small-cap context: Small-cap CFFO/NI often diverges from working-capital swings, not necessarily manipulation.
!
C2Free Cash Flow
FCF is negative ($-0.2B)
✓
C3Accruals Ratio
Accruals ratio = -1.7%. Low accruals
✓
C4Cash vs Debt
Cash $0.3B covers debt $0.0B
04
Balance Sheet Health
✓
D1Goodwill + Intangibles
No goodwill. Clean balance sheet
✓
D2Leverage
Debt/EBITDA = -0.0x. Healthy
—
D3Soft Asset Growth
Insufficient data
—
D4Asset Impairment
No write-off data
05
Acquisition Risk
✓
E1Serial Acquirer FCF
FCF after acquisitions positive
✓
E2Goodwill Surge
No goodwill
06
Manipulation Score
—
F1Beneish M-Score
Insufficient data
05
Altman Z-Score
10.94
Safe Zone0 Distress1.102.605.0+ Safe
0.9213
Liquidity
-1.2145
Cumulative profit
-0.5329
Operating efficiency
11.8414
Leverage
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25